166 related articles for article (PubMed ID: 37147682)
21. [Health care costs of acute myocardial infarction in Hungary, 2003-2005].
Gulácsi L; Májer I; Boncz I; Brodszky V; Merkely B; Maurovich HP; Kárpáti K
Orv Hetil; 2007 Jul; 148(27):1259-66. PubMed ID: 17604262
[TBL] [Abstract][Full Text] [Related]
22. [Experiences with price competition of biosimilar drugs in Hungary].
Hornyák L; Nagy Z; Tálos Z; Endrei D; Ágoston I; Csákvári T; Boncz I
Acta Pharm Hung; 2014; 84(2):83-7. PubMed ID: 25167704
[TBL] [Abstract][Full Text] [Related]
23. Developing competitive and sustainable Polish generic medicines market.
Simoens S
Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
[TBL] [Abstract][Full Text] [Related]
24. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
Lee L; Kim H
Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
[TBL] [Abstract][Full Text] [Related]
25. [Health related costs of smoking from the viewpoint of the Health Insurance Fund in Hungary].
Gresz M; Nagy J; Freyler P
Orv Hetil; 2012 Mar; 153(9):344-50. PubMed ID: 22348850
[TBL] [Abstract][Full Text] [Related]
26. [Annual epidemiological and health insurance disease burden of pertrochanteric fractures in Hungary].
Gazsó T; Elmer D; Endrei D; Sebestyén A; Kajos LF; Wiegand N; Boncz I
Orv Hetil; 2021 Mar; 162(162 Suppl 1):46-53. PubMed ID: 33774608
[TBL] [Abstract][Full Text] [Related]
27. Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.
Kwon HY; Godman B
BMC Health Serv Res; 2016 Apr; 16():130. PubMed ID: 27080530
[TBL] [Abstract][Full Text] [Related]
28. Expenditures Of Metabolic Diseases - An Estimation on National Health Care Expenditures of Diabetes and Obesity, Hungary 2013.
Iski G; Rurik SE; Rurik I
Exp Clin Endocrinol Diabetes; 2019 Jan; 127(1):62-67. PubMed ID: 29966152
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the Korean generic medicine market: Factors affecting the market share of generic medicines.
Kim DS; Shin J; Chung J
Clin Transl Sci; 2022 Feb; 15(2):433-441. PubMed ID: 34585837
[TBL] [Abstract][Full Text] [Related]
30. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
[TBL] [Abstract][Full Text] [Related]
31. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
32. [Health insurance reimbursement of dental care in Hungary].
Marada G; Nagy A; Benke B; Boncz I
Fogorv Sz; 2012 Mar; 105(1):3-8. PubMed ID: 22530363
[TBL] [Abstract][Full Text] [Related]
33. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
34. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
35. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
36. Parallel trade of pharmaceuticals: The Danish market for statins.
Méndez SJ
Health Econ; 2018 Feb; 27(2):333-356. PubMed ID: 28868645
[TBL] [Abstract][Full Text] [Related]
37. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
38. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
[TBL] [Abstract][Full Text] [Related]
39. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
Thai LP; Moss JR; Godman B; Vitry AI
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
[TBL] [Abstract][Full Text] [Related]
40. [Physiotherapy from the view of health insurance financing].
Géher P
Orv Hetil; 2013 Dec; 154(48):1917-23. PubMed ID: 24273291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
